Takeaway
- A cream formation containing hyaluronic acid 5% complexed with bacterial wall-derived glycoprotein and peptide glycan complex (EDS) is associated with clinical improvement of facial seborrheic dermatitis (SD).
Why this matters
- The cream appears to improve clinical symptoms and equilibrate the facial bacterial microbiota.
Key results
- EDS cream was associated with a 70% reduction in Investigator’s Global Assessment (IGA) score at week 3 (P=.001) and an 88% reduction at week 6 (P=.0001).
- Scaling score was reduced 60% at week 3 and 86% at week 6 (no statistics shown).
- Erythema score was reduced 57% at week 3 and 89% at week 6 (P=.001).
- Treatment was associated with an increase in Cutibacterium and a reduction in Staphylococcus bacteria.
- No local adverse effects were reported.
Study design
- 75 patients with moderate to severe SD were treated with EDS cream twice daily, and analyzed for outcomes.
- Funding: Cantabria Labs Difa Cooper.
Limitations
- Small patient sample size.
- No comparator.
References
References